Jennifer K Lue1, Jennifer E Amengual2. 1. Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, 51 W 51st Street, Suite 200, New York, NY, 10019, USA. 2. Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, 51 W 51st Street, Suite 200, New York, NY, 10019, USA. jea2149@columbia.edu.
Abstract
PURPOSE OF REVIEW: Enhancer of Zeste Homolog 2 (EZH2) is histone methyltransferase and catalyzes the methylation of histone 3 lysine 27, a mark of transcriptional repression. Various studies have elucidated the complex role of EZH2 in both normal biology and tumorigenesis. Here, we critically review the emerging role of EZH2 in malignancies, the development of small molecule inhibitors of EZH2, and their application in lymphoma. RECENT FINDINGS: Activating mutations and overexpression of EZH2 are found in non-Hodgkin lymphoma (NHL). As a result, several EZH2 inhibitors have been developed and entered clinical investigation. Tazemetostat, first-in-class EZH2 inhibitor, demonstrated enhanced clinical activity in mutant follicular lymphoma and diffuse large B cell lymphoma. With the early activity noted by tazemetostat in B cell lymphomas, the role of EZH2 inhibition in NHL is becoming more evident. This can be leveraged in future rationale combinations to enhance the activity of EZH2 inhibitors.
PURPOSE OF REVIEW: Enhancer of Zeste Homolog 2 (EZH2) is histone methyltransferase and catalyzes the methylation of histone 3 lysine 27, a mark of transcriptional repression. Various studies have elucidated the complex role of EZH2 in both normal biology and tumorigenesis. Here, we critically review the emerging role of EZH2 in malignancies, the development of small molecule inhibitors of EZH2, and their application in lymphoma. RECENT FINDINGS: Activating mutations and overexpression of EZH2 are found in non-Hodgkin lymphoma (NHL). As a result, several EZH2 inhibitors have been developed and entered clinical investigation. Tazemetostat, first-in-class EZH2 inhibitor, demonstrated enhanced clinical activity in mutant follicular lymphoma and diffuse large B cell lymphoma. With the early activity noted by tazemetostat in B cell lymphomas, the role of EZH2 inhibition in NHL is becoming more evident. This can be leveraged in future rationale combinations to enhance the activity of EZH2 inhibitors.
Authors: Jennifer E Amengual; Sean Clark-Garvey; Matko Kalac; Luigi Scotto; Enrica Marchi; Ellen Neylon; Paul Johannet; Ying Wei; Jasmine Zain; Owen A O'Connor Journal: Blood Date: 2013-08-02 Impact factor: 22.113
Authors: Michael T McCabe; Alan P Graves; Gopinath Ganji; Elsie Diaz; Wendy S Halsey; Yong Jiang; Kimberly N Smitheman; Heidi M Ott; Melissa B Pappalardi; Kimberly E Allen; Stephanie B Chen; Anthony Della Pietra; Edward Dul; Ashley M Hughes; Seth A Gilbert; Sara H Thrall; Peter J Tummino; Ryan G Kruger; Martin Brandt; Benjamin Schwartz; Caretha L Creasy Journal: Proc Natl Acad Sci U S A Date: 2012-02-08 Impact factor: 11.205
Authors: S Eckerle; V Brune; C Döring; E Tiacci; V Bohle; C Sundström; R Kodet; M Paulli; B Falini; W Klapper; A B Chaubert; K Willenbrock; D Metzler; A Bräuninger; R Küppers; M-L Hansmann Journal: Leukemia Date: 2009-08-06 Impact factor: 11.528
Authors: Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour Journal: N Engl J Med Date: 2015-12-06 Impact factor: 91.245
Authors: Rishi G Vaswani; Victor S Gehling; Les A Dakin; Andrew S Cook; Christopher G Nasveschuk; Martin Duplessis; Priyadarshini Iyer; Srividya Balasubramanian; Feng Zhao; Andrew C Good; Robert Campbell; Christina Lee; Nico Cantone; Richard T Cummings; Emmanuel Normant; Steven F Bellon; Brian K Albrecht; Jean-Christophe Harmange; Patrick Trojer; James E Audia; Ying Zhang; Neil Justin; Shuyang Chen; Jon R Wilson; Steven J Gamblin Journal: J Med Chem Date: 2016-10-28 Impact factor: 7.446
Authors: Rui Liang; Daisuke Tomita; Yusuke Sasaki; John Ginn; Mayako Michino; David J Huggins; Leigh Baxt; Stacia Kargman; Maaz Shahid; Kazuyoshi Aso; Mark Duggan; Andrew W Stamford; Elisa DeStanchina; Nigel Liverton; Peter T Meinke; Michael A Foley; Richard E Phillips Journal: ACS Med Chem Lett Date: 2022-02-10 Impact factor: 4.345
Authors: Devin Dersh; James D Phelan; Megan E Gumina; Boya Wang; Jesse H Arbuckle; Jaroslav Holly; Rigel J Kishton; Tovah E Markowitz; Mina O Seedhom; Nathan Fridlyand; George W Wright; Da Wei Huang; Michele Ceribelli; Craig J Thomas; Justin B Lack; Nicholas P Restifo; Thomas M Kristie; Louis M Staudt; Jonathan W Yewdell Journal: Immunity Date: 2020-12-02 Impact factor: 31.745